Literature DB >> 34655412

Epithelioid Soft Tissue Neoplasm of the Soft Palate with a PTCH1-GLI1 Fusion: A Case Report and Review of the Literature.

Ilmo Leivo1, Alena Skálová2,3, Natálie Klubíčková4,5,6, Zdeněk Kinkor2,3, Michael Michal2,3, Martina Baněčková2,3, Veronika Hájková7, Jaroslav Michálek8, Richard Pink9, Zdeněk Dvořák10, Michal Michal2,3.   

Abstract

GLI1 fusions involving ACTB, MALAT1, PTCH1 and FOXO4 genes have been reported in a subset of malignant mesenchymal tumors with a characteristic nested epithelioid morphology and frequent S100 positivity. Typically, these multilobulated tumors consist of uniform epithelioid cells with bland nuclei and are organized into distinct nests and cords with conspicuously rich vasculature. We herein expand earlier findings by reporting a case of a 34-year-old female with an epithelioid mesenchymal tumor of the palate. The neoplastic cells stained positive for S100 protein and D2-40, whereas multiple other markers were negative. Genetic alterations were investigated by targeted RNA sequencing, and a PTCH1-GLI1 fusion was detected. Epithelioid mesenchymal tumors harboring a PTCH1-GLI1 fusion are vanishingly rare with only three cases reported so far. Due to the unique location in the mucosa of the soft palate adjacent to minor salivary glands, multilobulated growth, nested epithelioid morphology, focal clearing of the cytoplasm, and immunopositivity for S100 protein and D2-40, the differential diagnoses include primary salivary gland epithelial tumors, in particular myoepithelioma and myoepithelial carcinoma. Another differential diagnostic possibility is the ectomesenchymal chondromyxoid tumor. Useful diagnostic clues for tumors with a GLI1 rearrangement include a rich vascular network between the nests of neoplastic cells, tumor tissue bulging into vascular spaces, and absence of SOX10, GFAP and cytokeratin immunopositivity. Identifying areas with features of GLI1-rearranged tumors should trigger subsequent molecular confirmation. This is important for appropriate treatment measures as PTCH1-GLI1 positive mesenchymal epithelioid neoplasms have a propensity for locoregional lymph node and distant lung metastases.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Epithelioid soft tissue neoplasm; Hedgehog signaling pathway; Oral cavity; PTCH1-GLI1 gene fusion; S100 protein; Soft palate

Mesh:

Substances:

Year:  2021        PMID: 34655412      PMCID: PMC9187807          DOI: 10.1007/s12105-021-01388-4

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  20 in total

1.  A Distinct Malignant Epithelioid Neoplasm With GLI1 Gene Rearrangements, Frequent S100 Protein Expression, and Metastatic Potential: Expanding the Spectrum of Pathologic Entities With ACTB/MALAT1/PTCH1-GLI1 Fusions.

Authors:  Cristina R Antonescu; Narasimhan P Agaram; Yun-Shao Sung; Lei Zhang; David Swanson; Brendan C Dickson
Journal:  Am J Surg Pathol       Date:  2018-04       Impact factor: 6.394

2.  Gastroblastoma harbors a recurrent somatic MALAT1-GLI1 fusion gene.

Authors:  Rondell P Graham; Asha A Nair; Jaime I Davila; Long Jin; Jin Jen; William R Sukov; Tsung-Teh Wu; Henry D Appelman; Jorge Torres-Mora; Kyle D Perry; Lizhi Zhang; Sara M Kloft-Nelson; Ryan A Knudson; Patricia T Greipp; Andrew L Folpe
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

Review 3.  Pericytoma With t(7;12): The First Ovarian Case Reported and a Review of the Literature.

Authors:  Nicholas Wee Chong Koh; Wan Yi Seow; York Tien Lee; Joyce Ching Mei Lam; Derrick Wen Quan Lian
Journal:  Int J Gynecol Pathol       Date:  2019-09       Impact factor: 2.762

4.  Cyclin D1 Expression in Ectomesenchymal Chondromyxoid Tumor of the Anterior Tongue.

Authors:  Jan Laco; Radovan Mottl; Walter Höbling; Stephan Ihrler; Petr Grossmann; Alena Skalova; Ales Ryska
Journal:  Int J Surg Pathol       Date:  2016-05-29       Impact factor: 1.271

5.  Pericytoma With t(7;12) and ACTB-GLI1 Fusion: Reevaluation of an Unusual Entity and its Relationship to the Spectrum of GLI1 Fusion-related Neoplasms.

Authors:  Darcy A Kerr; Andre Pinto; Ty K Subhawong; Breelyn A Wilky; Matthew P Schlumbrecht; Cristina R Antonescu; G Petur Nielsen; Andrew E Rosenberg
Journal:  Am J Surg Pathol       Date:  2019-12       Impact factor: 6.394

6.  Recurrent MALAT1-GLI1 oncogenic fusion and GLI1 up-regulation define a subset of plexiform fibromyxoma.

Authors:  Lien Spans; Christopher Dm Fletcher; Cristina R Antonescu; Alexandre Rouquette; Jean-Michel Coindre; Raf Sciot; Maria Debiec-Rychter
Journal:  J Pathol       Date:  2016-05-20       Impact factor: 7.996

7.  A Malignant Neoplasm From the Jejunum With a MALAT1-GLI1 Fusion and 26-Year Survival History.

Authors:  Owen William John Prall; Christopher Robert Edward McEvoy; David John Byrne; Amir Iravani; Judy Browning; David Yew-Huong Choong; Bhargavi Yellapu; Sophie O'Haire; Kortnye Smith; Stephen James Luen; Paul Leslie Ross Mitchell; Jayesh Desai; Stephen Bernard Fox; Andrew Fellowes; Huiling Xu
Journal:  Int J Surg Pathol       Date:  2020-01-13       Impact factor: 1.271

Review 8.  Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors.

Authors:  Tadas K Rimkus; Richard L Carpenter; Shadi Qasem; Michael Chan; Hui-Wen Lo
Journal:  Cancers (Basel)       Date:  2016-02-15       Impact factor: 6.639

Review 9.  Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells.

Authors:  Ita Novita Sari; Lan Thi Hanh Phi; Nayoung Jun; Yoseph Toni Wijaya; Sanghyun Lee; Hyog Young Kwon
Journal:  Cells       Date:  2018-11-10       Impact factor: 6.600

10.  Integrated diagnosis based on transcriptome analysis in suspected pediatric sarcomas.

Authors:  Daisuke Ichikawa; Kyoko Yamashita; Yusuke Okuno; Hideki Muramatsu; Norihiro Murakami; Kyogo Suzuki; Daiei Kojima; Shinsuke Kataoka; Motoharu Hamada; Rieko Taniguchi; Eri Nishikawa; Nozomu Kawashima; Atsushi Narita; Nobuhiro Nishio; Asahito Hama; Kenji Kasai; Seiji Mizuno; Yoshie Shimoyama; Masato Nakaguro; Hajime Okita; Seiji Kojima; Atsuko Nakazawa; Yoshiyuki Takahashi
Journal:  NPJ Genom Med       Date:  2021-06-15       Impact factor: 8.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.